Technical Analysis for KRON - Kronos Bio, Inc.

Grade Last Price % Change Price Change
F 31.57 -1.22% -0.39
KRON closed down 1.22 percent on Friday, January 15, 2021, on 68 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Up
Historical KRON trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
20 DMA Resistance Bearish -1.22%
50 DMA Support Bullish -1.22%
NR7 Range Contraction -1.22%
20 DMA Resistance Bearish -1.80%
Crossed Above 50 DMA Bullish -1.80%
180 Bullish Setup Bullish Swing Setup -1.80%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.80%
20 DMA Resistance Bearish 1.41%
Older End-of-Day Signals for KRON ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California.
Classification

Sector: Other
Industry: Other
Keywords: Biopharmaceutical Biology Solid Tumors Acute Myeloid Leukemia Enzymes Tyrosine Kinase Transcription Cancer Therapeutics Novel Cancer Transcription Factors Transcription Factor Cyclin Dependent Kinase Entospletinib Kronos Morpholines

Is KRON a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 39.6
52 Week Low 25.5
Average Volume 220,677
200-Day Moving Average 0.00
50-Day Moving Average 31.73
20-Day Moving Average 32.43
10-Day Moving Average 31.01
Average True Range 2.48
ADX 16.15
+DI 21.79
-DI 17.41
Chandelier Exit (Long, 3 ATRs ) 31.53
Chandelier Exit (Short, 3 ATRs ) 34.96
Upper Bollinger Band 37.07
Lower Bollinger Band 27.79
Percent B (%b) 0.41
BandWidth 28.63
MACD Line -0.16
MACD Signal Line -0.15
MACD Histogram -0.008
Fundamentals Value
Market Cap 1.77 Billion
Num Shares 56 Million
EPS
Price-to-Sales 0.00
Price-to-Book 23.24
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 34.50
Resistance 3 (R3) 34.48 33.48 34.01
Resistance 2 (R2) 33.48 32.74 33.49 33.84
Resistance 1 (R1) 32.53 32.28 33.01 32.55 33.68
Pivot Point 31.53 31.53 31.77 31.54 31.53
Support 1 (S1) 30.58 30.79 31.06 30.60 29.46
Support 2 (S2) 29.58 30.33 29.59 29.30
Support 3 (S3) 28.63 29.58 29.13
Support 4 (S4) 28.65